Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer

Gouji Toyokawa, Kazuki Takada, Tetsuzo Tagawa, Fumihiko Kinoshita, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Fumihiko Hirai, Yuichi Yamada, Ryuji Hamamoto, Yoshinao Oda, Yoshihiko Maehara

研究成果: Contribution to journalArticle査読

6 被引用数 (Scopus)

抄録

Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher’s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.

本文言語英語
ページ(範囲)3707-3711
ページ数5
ジャーナルAnticancer research
38
6
DOI
出版ステータス出版済み - 6 2018

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル